| And as I mentioned above, (Nasdaq: CERO) has several potential breakout catalysts that could be worth taking notice of at the moment. Check these out...
#1. CERO Potential Catalyst - A Low Float Under 2Mn Shares Could Create A Volatile Environment.
According to the Yahoo Finance website, CERO has a very low float.
In fact, the website reports this profile to have approximately 1.1Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility potential.
If the company provides more positive company news before the end of 2025, could it create a near term spark when paired with the volatility potential? -----
#2. CERO Potential Catalyst - An Analyst $30 Price Target Suggests 1,100+% Potential Upside.
According to MarketBeat, D. Boral Capital recently reiterated CERo Therapeutics with an $30 price target.
Citing the company’s innovative T cell engineering platform for cancer treatment, D. Boral Capital's target suggests a potential upside well over 1,100% from Monday's close.
CERo’s proprietary technology aims to enhance both innate and adaptive immune responses, positioning it as a leader in solid tumor therapies.
Recent FDA approvals and patent allowances further strengthen its clinical and intellectual property position, with key trial milestones anticipated in 2025 and 2026. -----
#3. CERO Potential Catalyst - CERo Completes First Cohort Of Key Phase 1 Clinical Trial Of CER-1236.
CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML
Study’s Dose Escalation Safety Committee approves initiation of Cohort 2 with fourth patient to receive increase in initial dose pending regulatory approval
...
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanisms, announces it has concluded the first cohort of its Phase 1 CER-1236 clinical trial focused on patients with acute myeloid leukemia (AML). The conclusion of the first cohort follows observation of cell expansion consistent with preclinical expectations, with no dose-limiting toxicities observed. The initial dose chosen for Cohort One was identical to the standard dose administered in CAR T therapy to B-cell lymphoma patients, where toxicity is commonly observed and treated in hospital. Additional dose infusions were administered to the second and third patients as the company continues forward with dose-finding investigations.
The conclusion of the first cohort follows observations of cell expansion with no dose-limiting toxicities. Following approval of the Dose Escalation Safety Committee, the investigators have agreed to initiate the second cohort of the study in which three new patients will receive an increase in the starting dosage from the previous cohort.
As the second cohort begins, the Company also plans to provide an additional infusion of CER-1236 to the second subject of Cohort One based on encouraging pharmacokinetic data and interest from the patient and treating physician. This approach explores whether multiple infusions may provide an alternative to dose intensification through a single larger initial dose.
Robert Sikorski, M.D., Ph.D., CERo’s Chief Medical Officer, noted, “Completion of the first cohort without any dose-limiting toxicities and in-vivo cell expansion of CER-1236 therapeutic cells represent important early steps in this study. The data collected to date support moving to the next planned dose level in accordance with the trial protocol. As we advance, we will continue close safety monitoring and systematic evaluation of pharmacokinetic and clinical data to inform subsequent stages of development.”
...
CERo CEO Chris Ehrlich added, “The completion of the first cohort represents important progress in the ongoing Phase 1 trial of CER-1236. We remain focused on advancing the current clinical trial and wish to clarify that the Company is not currently pursuing acquisition or partnership discussions. At this time, we are dedicated to completing our current dose escalating Phase 1 trial. Once we have further advanced the trial and have achieved the clinical data package we are seeking, we will explore all potential options that would best achieve optimal shareholder value.”
Read the full article here. -----
#4. CERO Potential Catalyst - CERo CEO Shares That The Company's IP Portfolio Is Stronger Than Ever After Key Patent-Related Updates.
CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041
Additional patent granted from the Japanese patent office now results in 20 granted patents and allowed applications covering the compound and its underlying technology
SOUTH SAN FRANSCISCO, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative cellular immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces the Company received a Notice of Allowance from the U.S. Patent and Trademark Office for its Application 19/019,111. The patent that will issue will provide the Company with both composition of matter protection for CER-1236 and protection for the use of CER-1236 to treat cancer, through 2041. Upon issuance, this patent will provide the most comprehensive protection specific to CER-1236 to date.
The Company also obtained a patent in Japan, which provides protection for the CER platform. The newly allowed U.S. application and issued Japanese patent join 17 other patents and another allowed application, bringing the total to 18 patents and 2 allowed applications covering CER-1236 and its platform technology internationally.
“Our intellectual property portfolio is stronger than ever, with our lead compound now receiving the Notice of Allowance in the United States. Combined with our recent announcements of Fast Track and Orphan Drug Designations from the FDA, we are in a strong regulatory position with regard to exclusivity. We are also continuing to make important progress in our ongoing Phase 1 clinical trial and look forward to continued updates on all developments,” said CERo Therapeutics CEO Chris Ehrlich.
Read the full article here. -----
#5. CERO Potential Catalyst - A Major Regulatory Milestone Is Met With The U.S. FDA Granting Fast Track Designation.
CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)
Regulatory milestone adds to its existing Orphan Drug Designation, creating additional regulatory and financial advantages for the Company’s lead cancer immunotherapy program
SOUTH SAN FRANSCISCO, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative cellular immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to the Company’s lead investigational compound, CER-1236 for Acute Myeloid Leukemia (AML). This designation is in addition to the existing Orphan Drug Designation for the compound.
“These FDA designations are important additional validation with regard to the urgency of the condition as well as the potential that the agency sees in the existing data as submitted. Further, these designations help to decrease the potential time to market and provide additional benefits across the FDA process that are expected to prove both medically and financially valuable. We continue to believe that CER-1236 represents a truly novel approach to cancer immunotherapy and are gratified by this regulatory milestone,” said CERo Therapeutics CEO Chris Ehrlich.
FDA’s Fast Track Designation is designed to accelerate the development and review of therapies for serious or life-threatening conditions with unmet medical need. The designation provides CERo with the opp. for increased FDA interactions, potential eligibility for priority review, and the ability to submit data on a rolling basis. Further, it also requires the Company to potentially provide expanded access to the investigational drug on an as-approved basis under pre-specified conditions.
...
Read the full article here. -----
(Nasdaq: CERO) Recap - The Top 5 Potential Breakout Catalysts On Watch
#1. A Low Float Under 2Mn Shares Could Create A Volatile Environment.
#2. An Analyst $30 Price Target Suggests 1,100+% Potential Upside.
#3. CERo Completes First Cohort Of Key Phase 1 Clinical Trial Of CER-1236.
#4. CERo CEO Shares That The Company's IP Portfolio Is Stronger Than Ever After Key Patent-Related Updates.
#5. A Major Regulatory Milestone Is Met With The U.S. FDA Granting Fast Track Designation. -----
It's official. Coverage is now underway on CERo Therapeutics Holdings, Inc. (Nasdaq: CERO).
Be on the lookout for updates coming shortly.
Sincerely, Kai Parker StockWireNews
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 10/21/2025 and ending on 10/21/2025 to publicly disseminate information about (CERO:US) via digital communications. Under this agreement, SWN Media LLC has been paid twenty thousand USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid thirty seven thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (CERO:US).
Please see important disclosure information here: https://stockwirenews.com/disclosure/cero-sdvr9/#details | 
